The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula I:
wherein A, Q, X
1
, X
2
, Y, R
1
, R
2
, R
3
, R
4
, R
4
′, R
5
, R
6
and R
6
′ are as described herein.
The present disclosure is generally directed to antiviral compounds, and more specifically directed to compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such compounds, and methods for inhibiting the function of the NS5A protein.